Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • Vascular Malformations (Apr 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact

Citations to this article

The endothelial cell ecto-ADPase responsible for inhibition of platelet function is CD39.
A J Marcus, … , R B Gayle, C R Maliszewski
A J Marcus, … , R B Gayle, C R Maliszewski
Published March 15, 1997
Citation Information: J Clin Invest. 1997;99(6):1351-1360. https://doi.org/10.1172/JCI119294.
View: Text | PDF
Research Article Article has an altmetric score of 9

The endothelial cell ecto-ADPase responsible for inhibition of platelet function is CD39.

  • Text
  • PDF
Abstract

We previously demonstrated that when platelets are in motion and in proximity to endothelial cells, they become unresponsive to agonists (Marcus, A.J., L.B. Safier, K.A. Hajjar, H.L. Ullman, N. Islam, M.J. Broekman, and A.M. Eiroa. 1991. J. Clin. Invest. 88:1690-1696). This inhibition is due to an ecto-ADPase on the surface of endothelial cells which metabolizes ADP released from activated platelets, resulting in blockade of the aggregation response. Human umbilical vein endothelial cells (HUVEC) ADPase was biochemically classified as an E-type ATP-diphosphohydrolase. The endothelial ecto-ADPase is herein identified as CD39, a molecule originally characterized as a lymphoid surface antigen. All HUVEC ecto-ADPase activity was immunoprecipitated by monoclonal antibodies to CD39. Surface localization of HUVEC CD39 was established by confocal microscopy and flow cytometric analyses. Transfection of COS cells with human CD39 resulted in both ecto-ADPase activity as well as surface expression of CD39. PCR analyses of cDNA obtained from HUVEC mRNA and recombinant human CD39 revealed products of the same size, and of identical sequence. Northern blot analyses demonstrated that HUVEC express the same sized transcripts for CD39 as MP-1 cells (from which CD39 was originally cloned). We established the role of CD39 as a prime endothelial thromboregulator by demonstrating that CD39-transfected COS cells acquired the ability to inhibit ADP-induced aggregation in platelet-rich plasma. The identification of HUVEC ADPase/CD39 as a constitutively expressed potent inhibitor of platelet reactivity offers new prospects for antithrombotic therapeusis.

Authors

A J Marcus, M J Broekman, J H Drosopoulos, N Islam, T N Alyonycheva, L B Safier, K A Hajjar, D N Posnett, M A Schoenborn, K A Schooley, R B Gayle, C R Maliszewski

×

Total citations by year

Year: 2025 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 2008 2007 2006 2005 2004 2003 2002 2001 2000 1999 1998 1997 1990 1983 Total
Citations: 1 2 3 3 3 5 3 3 8 15 7 5 12 12 33 10 8 10 13 10 21 22 19 24 22 18 14 21 3 1 1 332
Citation information
This citation data is accumulated from CrossRef, which receives citation information from participating publishers, including this journal. Not all publishers participate in CrossRef, so this information is not comprehensive. Additionally, data may not reflect the most current citations to this article, and the data may differ from citation information available from other sources (for example, Google Scholar, Web of Science, and Scopus).

Citations to this article in year 2007 (13)

Title and authors Publication Year
Contribution of E-NTPDase1 (CD39) to renal protection from ischemia-reperfusion injury
A Grenz, H Zhang, M Hermes, T Eckle, K Klingel, DY Huang, CE Müller, SC Robson, H Osswald, HK Eltzschig
The FASEB Journal 2007
CD39/NTPDase-1 activity and expression in normal leukocytes
ED Pulte, MJ Broekman, KE Olson, JH Drosopoulos, JR Kizer, N Islam, AJ Marcus
Thrombosis Research 2007
The Nucleoside Triphosphate Diphosphohydrolase-1/CD39 Is Incorporated into Human Immunodeficiency Type 1 Particles, Where It Remains Biologically Active
C Barat, G Martin, AR Beaudoin, J Sévigny, MJ Tremblay
Journal of Molecular Biology 2007
Targeted Deletion of Ectonucleoside Triphosphate Diphosphohydrolase 1/CD39 Leads to Desensitization of Pre- and Postsynaptic Purinergic P2 Receptors
U Schaefer, T Machida, MJ Broekman, AJ Marcus, R Levi
The Journal of pharmacology and experimental therapeutics 2007
Characterization of Rat NTPDase1, -2, and -3 Ectodomains Refolded from Bacterial Inclusion Bodies
M Zebisch, N Sträter
Biochemistry 2007
CD39 activity correlates with stage and inhibits platelet reactivity in chronic lymphocytic leukemia
D Pulte, KE Olson, MJ Broekman, N Islam, HS Ballard, RR Furman, AE Olson, AJ Marcus
Journal of Translational Medicine 2007
Platelet integrins and immunoreceptors
A Kasirer-Friede, ML Kahn, SJ Shattil
Immunological Reviews 2007
Specificity of the ecto-ATPase inhibitor ARL 67156 on human and mouse ectonucleotidases
SA Lévesque, EG Lavoie, J Lecka, F Bigonnesse, J Sévigny
British Journal of Pharmacology 2007
Characterization of Schistosoma mansoni ATPDase2 gene, a novel apyrase family member
J Levano-Garcia, RA Mortara, S Verjovski-Almeida, R DeMarco
Biochemical and Biophysical Research Communications 2007
Transient changes in the localization and activity of ecto-nucleotidases in rat hippocampus following lipopolysaccharide treatment
Á Kittel, B Sperlágh, J Pelletier, J Sévigny, TL Kirley
International Journal of Developmental Neuroscience 2007
Salutary roles of CD39 in transplantation
KM Dwyer, S Deaglio, S Crikis, W Gao, K Enjyoji, TB Strom, PJ Cowan, AJ d'Apice, SC Robson
Transplantation Reviews 2007
Cell Adhesion
A Goldstein
Tissue Engineering 2007
Constraints imposed by transmembrane domains affect enzymatic activity of membrane-associated human CD39/NTPDase1 mutants
E Musi, N Islam, JH Drosopoulos
Archives of Biochemistry and Biophysics 2007

Advertisement

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts

Referenced in 27 patents
111 readers on Mendeley
See more details